- Home
- INMB vs MAIA Comparison
INMB vs MAIA Comparison
Compare INMB & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INMB | MAIA |
|---|---|---|
| Founded | 2015 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.1M | 44.9M |
| IPO Year | 2019 | 2022 |
Fundamental Metrics
Financial Performance| Metric | INMB | MAIA |
|---|---|---|
| Price | $1.59 | $1.34 |
| Analyst Decision | Hold | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $4.30 | N/A |
| AVG Volume (30 Days) | 488.2K | ★ 865.2K |
| Earning Date | 10-30-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $50,000.00 | N/A |
| Revenue This Year | $264.29 | N/A |
| Revenue Next Year | $14,337.26 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 19.05 | N/A |
| 52 Week Low | $1.38 | $0.87 |
| 52 Week High | $11.64 | $2.74 |
Technical Indicators
Market Signals| Indicator | INMB | MAIA |
|---|---|---|
| Relative Strength Index (RSI) | 38.47 | 53.59 |
| Support Level | $1.75 | $1.33 |
| Resistance Level | $1.90 | $1.64 |
| Average True Range (ATR) | 0.12 | 0.15 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 0.00 | 40.32 |
Price Performance
Historical ComparisonAbout INMB INmune Bio Inc.
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.